Condition
Location

13 Eosinophilic Esophagitis Trials

Power is an online platform that helps thousands of Eosinophilic Esophagitis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Image of trial facility.

CC-93538 for Eosinophilic Esophagitis

Indianapolis, Indiana
This trial aims to evaluate the ongoing safety and tolerability of CC-93538 in participants who were part of earlier studies involving this treatment.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 75
Sex:All
259 Participants Needed
Image of trial facility.

CC-93538 for Eosinophilic Esophagitis

Indianapolis, Indiana
Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: Placebo for Induction and Maintenance CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance CC-93538 360 mg SC once weekly for Induction and Maintenance
Pivotal Trial
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:12 - 75
Sex:All
399 Participants Needed
Image of trial facility.

Tezepelumab for Eosinophilic Esophagitis

Cincinnati, Ohio
This trial tests an injection treatment for people with a condition that causes swelling in the esophagus. The treatment aims to reduce this swelling by calming the immune system.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:12 - 80
Sex:All
360 Participants Needed
Image of trial facility.

Barzolvolimab for Eosinophilic Esophagitis

Cincinnati, Ohio
This trial is testing a medication called barzolvolimab. It aims to help adult patients with Eosinophilic Esophagitis, a condition affecting the esophagus. The study will check if barzolvolimab can reduce inflammation and improve symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
75 Participants Needed
Image of trial facility.

Alpha-proteinase Inhibitor for Eosinophilic Esophagitis

Cincinnati, Ohio
This trial is testing Zemaira, a medication that protects tissues from damage, in patients with Eosinophilic Esophagitis. These patients have chronic inflammation in their esophagus due to an overactive immune response. Zemaira works by blocking harmful enzymes to reduce inflammation and prevent further damage.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 70
Sex:All
15 Participants Needed
Image of trial facility.

Dupilumab for Eosinophilic Gastrointestinal Diseases

Cincinnati, Ohio
This trial is testing a new drug called dupilumab to see if it can help people aged 12 and older who have a condition that causes too many white blood cells to gather in their stomach and small intestine, leading to inflammation and damage. The study will compare the effects of dupilumab to another treatment and will also look at side effects and how the body reacts to the drug.
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:12+
Sex:All
279 Participants Needed
Image of trial facility.

Dupilumab for Esophagitis

Chicago, Illinois
This is parallel, Phase 4 study which consists of a 24 week (0.5 years) randomized, double blind, placebo controlled, 2-arm treatment period followed by an open label segment of 104 weeks (2 years) for a total of 128 weeks (2.5 years) to evaluate the effect of dupilumab treatment on esophageal function, and remodeling in adults with eosinophilic esophagitis. Duration of study period (per participant) * Screening period: Up to 12 weeks before Week 0 * Randomized double-blind period: 24 weeks * Open label period: 104 weeks * Post Investigational Medicinal Product (IMP) intervention follow-up period: up to 12 weeks or until the participants switch to commercialized dupilumab, whatever comes first. There will be ten (10) site visits, and five (5) direct-to-participant IMP delivery visits (except if prohibited by local regulatory authorities or if participant is not willing. In this case, IMP will be dispensed at the study site).
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18+
Sex:All
64 Participants Needed
Image of trial facility.

Decision Support for Eosinophilic Esophagitis

Ann Arbor, Michigan
The study team is conducting this project to learn more about how patients with eosinophilic esophagitis (EoE) like to use and receive educational materials about treatment options and treatment decision making. This study will assess the efficacy of a decision support intervention to make decisions about treatment and disease management for patients with EoE and will assess the feasibility and acceptability of the intervention to inform future R01-level studies. The study team hypothesize that deploying the intervention will be feasible, and it will demonstrate high acceptability among EoE patients. Additionally, that patients that use the intervention (vs general education about EoE) will report greater treatment knowledge, increased readiness to choose a therapy, adherence to therapy, and follow-up.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
40 Participants Needed
Image of trial facility.

Budesonide for Eosinophilic Esophagitis

Cleveland, Ohio
The purpose of this study is to prove the non-inferiority of a 6-weeks treatment with 1 mg budesonide orodispersible tablets BID versus 2 mg budesonide orodispesible tabletss for the induction of clinico-pathological remission in adult patients with active eosinophilic esophagitis.
No Placebo Group
Prior Safety Data
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 75
Sex:All
308 Participants Needed
Image of trial facility.

Dupilumab for Eosinophilic Esophagitis

Chapel Hill, North Carolina
The purpose of this research study is to determine how well an FDA-approved drug, dupilumab, works to treat patients with severe strictures and active Eosinophilic Esophagitis (EoE). This is an open-label study, meaning everyone in the study will receive dupilumab. Participants will have a screening visit where they will complete surveys and undergo an endoscopy (EGD). Blood and biopsies (small tissue samples) will also be collected. If eligible and enrolled into the study, participants will receive weekly subcutaneous (under the skin) injections of dupilumab for 52 weeks (one year). The first dose of dupilumab will be administered at the week 1 visit by a clinician and participants will receive training on how to self-administer the remaining doses. Participants will return for study visits every at weeks 4, 8, 12, 18, 24, 30, 36, 44, and 52. During these visits, vital signs (temperature, heart rate, etc.) will be collected and participants will complete surveys. During visits at week 12, 24, and 52, blood will be collected and an endoscopy with biopsy will be performed. At 64 weeks (12 weeks after the last dose of dupilumab), participants assigned male at birth (AMAB) will be contacted about their / their partner's pregnancy status and participants assigned female at birth (AFAB) may be asked to come for an in-person visit to complete a urine pregnancy test.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:16+
Sex:All
30 Participants Needed
Image of trial facility.

Baked Milk for Eosinophilic Esophagitis

Rochester, Minnesota
This research is being done to see if patients with milk-triggered EoE are able to tolerate baked milk in their diet and if there is a threshold amount of straight milk that is tolerable.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 90
Sex:All
26 Participants Needed
Image of trial facility.

Individualized Elimination Diet for Eosinophilic Esophagitis

Chapel Hill, North Carolina
This is a randomized, double blind, sham-controlled, pilot/feasibility trial of individualized dietary elimination treatment.
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:16 - 80
Sex:All
100 Participants Needed
Image of trial facility.

Solrikitug for Eosinophilic Esophagitis

Harrisburg, Pennsylvania
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solrikitug in adult participants with eosinophilic esophagitis.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
157 Participants Needed
Page 1 of 1+

Frequently Asked Questions

How much do Eosinophilic Esophagitis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Eosinophilic Esophagitis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Eosinophilic Esophagitis trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Eosinophilic Esophagitis is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Eosinophilic Esophagitis medical study ?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Eosinophilic Esophagitis clinical trials ?

Most recently, we added Decision Support for Eosinophilic Esophagitis, Alpha-proteinase Inhibitor for Eosinophilic Esophagitis and Solrikitug for Eosinophilic Esophagitis to the Power online platform.

Other People Viewed

Deucravacitinib for Hidradenitis Suppurativa

Luspatercept for Thalassemia

Deep Brain Stimulation for Autism

LY3884961 for Gaucher Disease

nVNS for Traumatic Brain Injury-Induced Acute Respiratory Distress

Volixibat for Primary Biliary Cholangitis

Ankle Mobilization for Knee Pain

Muscle Fiber Fragment Treatment for Urinary Incontinence

Mirikizumab for Ulcerative Colitis

Itraconazole for Esophageal Cancer

Dry Needling for Knee Pain

HM15211 for Non-alcoholic Steatohepatitis (NASH)

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top